SV

Street Verdict

Analyst Scorecard

A record of what Chandan Taparia said publicly, with the source. Not advice.

“Bullish on Aurobindo Pharma, recommending a buy with a target price of ₹1,820 and a stop loss of ₹1,665. The stock is in an overall uptrend, trading in all-time high territory, reflecting strong bullish momentum. It has surpassed its previous swing high near ₹1,680, forming higher highs, and the RSI shows a bullish crossover.”

Chandan Taparia’s track record (trackable calls only): 352 graded calls · 95% CI 32–42%

Aurobindo PharmaBullishCalled 01 Sep 2026Graded 21 Nov 2026
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹1,820, stop ₹1,665, as stated.

No time frame is stated, so it is tracked until a close reaches ₹1,820 or ₹1,665: there is no fixed window.

The stop ₹1,665 was reached on a close before the target ₹1,820. Miss.

The grader’s working: R4 TARGET_CALL: entered ₹1648.2 on 2026-09-02 (next trading session's close); stop ₹1665 breached at close ₹1648.2 on 2026-09-02. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.

How it played out

How this is worked out
Target or stop first
The stop was reached on a close before the target was.
Time to target
The target was not reached on a close before the stop was.
Worst close against it
No close was ever against the call up to 2 Sep 2026, when the call was decided. Closing prices only; an intraday dip is never counted.

From the entry the grade used, on closing prices. This is a record of one past call and is not advice.

Tracking Aurobindo Pharma since this call

1-year tracking window
Read the original articleSee Chandan Taparia’s full track record